Clinical Trial

Clazakizumab vs. Placebo - COVID-19 Infection

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 31, 2020 (before its estimated December 31, 2020 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to investigate the effectiveness and safety of treatment with clazakizumab compared to a placebo (inactive substance). We are proposing to try this drug to treat coronavirus disease 2019 (COVID-19) infection. Patients with COVID-19 infection have been shown to have increases in certain inflammatory processes. Clazakizumab is an antibody (immune system protein) that blocks certain inflammatory processes. The treatment plan is to attempt to inhibit or block these inflammatory processes in order to try to limit the damage COVID-19 causes to the lungs.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-07-30.
Status change: Recruiting → Terminated 2026-06-09
Trial Details
NCT Number NCT04494724
Lead Sponsor The Methodist Hospital Research Institute
Conditions COVID-19 Infection
Enrollment 60 participants
Start Date 2020-07-13
Primary Completion 2020-12-31 (estimated)
Study Completion 2021-07-31 (estimated)
Updated on ClinicalTrials.gov 2020-07-31